Revance Therapeutics Inc - Company Profile
Powered by 
All the data and insights you need on Revance Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Revance Therapeutics Inc Strategy Report
- Understand Revance Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Business Description
Revance Therapeutics Inc (Revance Therapeutics) is a biotechnology company that is developing products for aesthetic medicine and unmet clinical need of therapeutic specialties, including dermatology and neurology.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
Revance Therapeutics conducts research to advance the development of novel neuromodulators for a wide range of therapeutic and aesthetic indications. The company is advancing botulinum toxin products: daxibotulinumtoxinA, a topical gel formulation as a needle-free approach for a wide range of therapeutic and aesthetic indications, such as facial wrinkles, chronic migraine, and muscle disorders and daxibotulinumtoxinA for injection (DAXI), an injectable formulation of botulinum toxin for the treatment of glabellar lines, cervical dystonia, and plantar fasciitis. In FY2022, Revance Therapeutics spent US$101.2 million towards its R&D activities. As of December 31, 2022, Revance Therapeutics held 312 issued patents and 99 pending patent applications of the 312 issued patents, the company holds rights to 44 issued patents in the US and rights for the rest issued patents in Australia, Brazil, Canada, China, Europe, Mexico, New Zealand, Hong Kong, Israel, Japan, Singapore, and South Korea. It also holds pending patent applications in the US, Australia, Brazil, Canada, China, Columbia, Europe, Japan, Mexico, New Zealand, Hong Kong, India, Israel, Philippines, Singapore and South Korea.
Business Segments
Overview
Includes the research and development of innovative aesthetic and therapeutic products, including DaxibotulinumtoxinA for Injection for various indications, including the RHA Collection of dermal fillers, resilient hyaluronic acid, and the onabotulinumtoxin, a biosimilar program in partnership with Viatris.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Includes the business of the HintMD platform, is a smart payment solutions which provides subscription and pay-over-time solutions that support practices for aesthetic treatment plans and enables practices to process payments for their patients.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer